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Orthostatic hypotension (OH) is a common and disabling symptom affecting Parkinson’s
disease (PD) patients. We present the effect of the different therapies commonly used
to manage PD on this clinical manifestation. For this purpose, we describe the rela-
tionship between OH and the current treatments employed in PD, such as L-DOPA,
dopaminergic agonists, and continuous dopaminergic stimulation therapies. Additionally,
we review the therapeutic measures that could be used to ameliorate OH. There are
different approaches to deal with this manifestation, including pharmacological and non-
pharmacological treatments, although none of them is specifically aimed for treating OH
in PD.
Keywords: treatment, orthostatic hypotension, dopamine agonists, L-DOPA, continuous dopaminergic stimulation,
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INTRODUCTION
After the first comprehensive description of the cardinal features
of Parkinson’s disease (PD) (Parkinson, 2002) many non-motor
features have been recognized (Hughes et al., 1992). One of the
most disabling is orthostatic hypotension (OH), which is defined
by a sustained reduction of systolic blood pressure (SBP) of at
least 20 mmHg or diastolic blood pressure (DBP) of 10 mmHg
within 3 min of standing or head-up tilt to at least 60 on a tilt table
(Kaufmann, 1996; Freeman et al., 2011).
The presumed pathophysiology of OH is related to the impair-
ment of sympathetic vasomotor neurons due to the neurode-
generative process of PD (Senard et al., 2001; Metzler et al.,
2012).
Growing attention has been paid to this non-motor feature
of the disease; especially since dopaminergic drugs were intro-
duced [l-DOPA and dopamine agonists (DA)] (Barbeau et al.,
1969; Calne et al., 1970; McDowell and Lee, 1970; Duby et al.,
1972).
Even in those cross-sectional initial descriptions, the frequency
of this symptom has been highlighted, affecting more than 30%
of the PD patients (Barbeau, 1969). A similar pooled estimated
prevalence has recently been reported in a systematic review
(Velseboer et al., 2011). Other inferences have showed higher fre-
quencies [41% (Kaufmann and Goldstein, 2007) and 47% in a
community-based study (Allcock et al., 2004)].
Additionally, its consequences are important as it may imply an
increased mortality and comorbidity (mainly owing to falls and
concomitant vascular disorders) (Fedorowski et al., 2010; Maule
et al., 2012).
In the current article, our aim is to review all the therapeutic
options available to treat this frequent and incapacitating symp-
tom, focusing on those aspects less studied. We begin describing
the influence that common drugs and advanced therapies used
in PD may exert on it. Thereafter, we detail non-pharmacological
approaches that could be employed to ameliorate this symptom.
We end summarizing the existing pharmacological options to
treat it.
THE EFFECT OF THE ANTI-PARKINSONIAN THERAPIES ON
ORTHOSTATIC HYPOTENSION
One of the initial steps required when assessing a patient who is
going to receive any anti-parkinsonian medication/treatment or
who needs a dose adjustment is to anticipate the potential effect
on his blood pressure, as it is one of the commonly related factors
to the appearance of OH (Perez-Lloret et al., 2012).
Several actions could help to improve the detection of this com-
plication, either by the physician or the subject. It seems reasonable
to instruct the patient about OH symptoms (lightheadedness or
dizziness after standing, fatigue, and others), although many cases
go unnoticed (Arbogast et al., 2009). An initial pressor response
assessment (blood pressure after standing) could be valuable to
have a simple measurement to monitor future changes, as this
measurement is one of the easiest ways to appraise OH in various
healthcare settings.
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Many caveats should be considered prior to establishing the
real influence of PD medications on OH. First, there are different
diagnostic criteria for defining OH. Additionally, much evidence
is based on cross-sectional analyses and other confounding effects,
as disease duration or previous autonomous nervous system dam-
age (Awerbuch and Sandyk, 1992; Muller et al., 2011), have not
always been considered.
We present the current evidence to estimate the potential role
of current PD treatments on OH. The influence of other drugs,
such as antidepressants, diuretics, and antihypertensives, is not
reviewed here. Nevertheless, they should be considered when deal-
ing with this complication and decreasing the dose or stopping the
responsible medication might be advisable.
L-DOPA
Orthostatic hypotension has been documented as a potential side
effect of l-DOPA therapy since its early use on PD (Barbeau, 1969).
Multiple evidence (Barbeau, 1969; Calne et al., 1970; Keenan, 1970;
McDowell and Lee, 1970; Goldberg and Whitsett, 1971; Hoehn,
1975; Camerlingo et al., 1990; Senard et al., 1997; Bouhaddi et al.,
2004) has supported this relationship with ranges of decline oscil-
lating from 4.6–20 mmHg in SBP to 2.1–5.0 mmHg in DBP. Other
studies failed to show any clear direct relationship (Sachs et al.,
1985; Goetz et al., 1986; Haapaniemi et al., 2000; Perez-Lloret et al.,
2012).
The size of the effect in the studies where a decrease on
blood pressure was measured is summarized in Table 1. Method-
ologically limited earlier studies (small sample, not randomized,
without blinding) suggested the role of fludrocortisone (0.05–
0.2 mg/q.d.) and etilefrine (5 mg/t.i.d.) for treating l-DOPA-
associated OH (Miller et al., 1973; Hoehn, 1975).
DOPAMINE AGONISTS
Likewise with l-DOPA, DA use has been commonly reported to
produce OH in PD (Guttman, 1997; Senard et al., 1997; Lieberman
et al., 1998; Korczyn et al., 1999; Pinter et al., 1999; Kujawa et al.,
2000; Brunt et al., 2002; Boehringer Ingelheim Pharmaceuticals,
2003; GlaxoSmithKline, 2003a,b; UCB, Inc, 2003; Poewe et al.,
2007), although not always symptomatic (Kujawa et al., 2000);
however, in some studies this relationship was not shown (Hubble
et al., 1995; Perez-Lloret et al., 2012).
The figures of patients treated with DA having OH are simi-
lar to that reported for l-DOPA (Stowe et al., 2008). With active
standing, 34% of the DA resulted in OH (Kujawa et al., 2000);
nonetheless, OH symptomatic cases listed in clinical trials ranged
from 4.6 to 44.0% of the participants (Guttman, 1997; Lieberman
et al., 1998; Pinter et al., 1999; Brunt et al., 2002; Boehringer Ingel-
heim Pharmaceuticals, 2003; GlaxoSmithKline, 2003a,b; UCB, Inc,
2003). The mean decrease of blood pressure was 16.1 mmHg in the
SBP and 2.8 mmHg in the DBP (see Table 1) (Haapaniemi et al.,
2000).
There is not an established causal relationship with a specific
agonist, as OH has been reported in users of ergotic and non-
ergotic compounds (Guttman, 1997; Korczyn et al., 1999; Haa-
paniemi et al., 2000; Kujawa et al., 2000; Korchounov et al., 2004;
Stowe et al., 2008), and in all the current pharmaceutical prepa-
rations (conventional, extended release, and patch prescription)
Table 1 | Lowering effect of PD treatments on blood pressure.
Reference SBP
change
DBP
change
Sample
size
l-DOPA Bouhaddi et al.
(2004)
8.1 5.0 18
Camerlingo et al.
(1990)
9.21 2.11 12
Barbeau et al.
(1969)
>202 Na 86
Calne et al. (1970) 8.7 4.4 20
Dopamine
agonists
(excluding
apomorphine)
Haapaniemi et al.
(2000)
16.13 2.83 17
Monoamine
Oxidase inhibitors
Churchyard et al.
(1999)
194 54 20
Haapaniemi et al.
(2000)
12.53 5.23 17
CDS therapies
DBS Stemper et al.
(2006)
17.75 −25 14
Apo Pahwa et al.
(2007b)
8.76 Not
reported
56
CDLI Pursiainen et al.
(2012)
23.2 9.1 9
CDS, continuous dopaminergic stimulation; DBS, deep brain stimulation; CDLI,
continuous duodenal l-DOPA infusion; Apo, apomorphine pump; BP, blood pres-
sure; SBP, systolic blood pressure; DBP, diastolic blood pressure; *values after
tilting in mmHg (positive figures indicate a decrease); 1BP 3 min after tilting and
2 year after starting l-DOPA therapy; 2mean decrease after l-DOPA therapy; 3the
blood-pressure reported is immediately after tilting; 4the blood-pressure reported
is 2 min after tilting; 5blood-pressure reported after tilting with stimulation on;
620 min after apomorphine injection on standing.
(Boehringer Ingelheim Pharmaceuticals, 2003; GlaxoSmithKline,
2003a,b; UCB, Inc, 2003; Poewe et al., 2007). There is no direct
comparison between all DA and many clinical trials have not
reported this adverse event (Giladi et al., 2007; Pahwa et al.,
2007a; Stocchi et al., 2008; Stowe et al., 2008; Poewe et al., 2011;
Schapira et al., 2011), so no clear conclusions can be drawn on
this issue. Additionally, studies that evaluated different agonists
yielded heterogeneous results. In a research involving bromocrip-
tine, ropinirole, selegiline, l-DOPA, and amantadine, an increased
frequency of OH was observed when therapies were combined (l-
DOPA plus another DA) and with all the DA (a slightly greater
increase was found with bromocriptine compared with ropini-
role) (Korchounov et al., 2004). In meta-analytic data addressing
the profile of adverse events of DA found no differences between
them compared with l-DOPA (Etminan et al., 2003) and only in
another meta-analytic study, an increased risk of OH was sug-
gested for cabergoline (Kulisevsky and Pagonabarraga, 2010). In
summary, no clear conclusions can be drawn concerning the risk
of OH with a specific DA.
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MONOAMINE OXIDASE INHIBITORS
Drugs that inhibit MAO-B selectively, as rasagiline and selegiline,
have been also recognized as a potential factor for inducing OH
(Churchyard et al., 1997, 1999; Turkka et al., 1997; Haapaniemi
et al., 2000; Bhattacharya et al., 2003; Abassi et al., 2004; Rascol
et al., 2005; Olanow et al., 2009; Tolosa and Stern, 2012). There have
been several studies evaluating the effect of selegiline (Churchyard
et al., 1997, 1999; Turkka et al., 1997; Bhattacharya et al., 2003;
Korchounov et al., 2004). The percentage of affected individuals
ranged from 30% (Churchyard et al., 1999) to 50% (Bhattacharya
et al., 2003) and the mean decrease oscillated between 10.4 and
19 mmHg (Churchyard et al., 1999; Bhattacharya et al., 2003) for
SBP and five to even an increase of 2 mmHg for DBP (Churchyard
et al., 1999; Bhattacharya et al., 2003) (Table 1). As with the pre-
viously reviewed treatments, the hypotensive effect observed with
selegiline was not greater than the one occurring with other drugs
such as l-DOPA (Bhattacharya et al., 2003) or DA (Haapaniemi
et al., 2000) except in one study (Korchounov et al., 2004). There
was an initial concern about an increased mortality associated to
selegiline, also suggesting a role of its autonomic adverse effects
on it, but this has been recently discarded (Lees, 1995; Ives et al.,
2004; Turnbull et al., 2005). In addition to OH, hypertensive crises
have been reported with selegiline (Rose et al., 2000; Ito et al.,
2001).
Rasagiline is a more recent IMAO-B widely used in the clini-
cal practice for its potential neuroprotective effect (Abassi et al.,
2004; Parkinson Study Group, 2004, 2005; Rascol et al., 2005, 2011;
Olanow et al., 2009; Tolosa and Stern, 2012). The percentage of
individuals with symptomatic OH was comprised of between 1.5
and 6.5% (Olanow et al., 2009; Tolosa and Stern, 2012). Some
of the clinical trials involving rasagiline did not make any com-
ment about the percentage of subjects with OH and the mean
decrease on blood pressure was not reported (Parkinson Study
Group, 2005).
OTHER COMMON PRESCRIBED AGENTS (L-DOPA METABOLISM
INHIBITORS, ANTICHOLINERGICS, AMANTADINE,
ACETYLCHOLINESTERASE INHIBITORS)
There are descriptions of OH occurring with other medica-
tions such as amantadine (Korchounov et al., 2004; Perez-Lloret
et al., 2012), and acetylcholinesterase inhibitors (in PD dementia)
(Novartis Pharmaceuticals, 2003b). The evidence with anticholin-
ergics is less clear, not increasing OH frequency (Martin et al.,
1974), but affecting cardiovascular reflexes (Korchounov et al.,
2004). The COMT inhibitors entacapone (Lyytinen et al., 2001;
Novartis Pharmaceuticals, 2003a; Olanow et al., 2004) and tol-
capone (Tolcapone Study Group, 1999; Koller et al., 2001), as
well as DOPA-decarboxylase inhibitors, showed no clear influence
on OH (Leibowitz and Lieberman, 1975; Rappelli et al., 1978),
except in one study where entacapone showed a protective effect
(Perez-Lloret et al., 2012).
IS THERE A DOSE-DEPENDENT EFFECT OR AN INFLUENCE OF
THERAPIES COMBINATIONS ON OH? WHEN DOES OH OCCUR IN
TREATED SUBJECTS?
It seems plausible, based on different observational approaches,
that higher doses of dopaminergic medications (Senard et al.,1997;
Allcock et al., 2006; Chitsaz et al., 2007) and combined therapies
(Korchounov et al., 2004) could also increase the chances of mani-
festing OH. Also some works have suggested that the main effect of
medications could be at the beginning of the therapy developing
some tolerance thereafter (Pathak and Senard, 2004).
Based on all these evidence, the possibility of OH should
be especially considered, when starting/adding a new drug or
increasing its dose as the probability of symptoms could increase.
CONTINUOUS DOPAMINERGIC STIMULATION THERAPIES
Deep brain stimulation
Cross-sectional studies have suggested a positive effect of subthal-
amic Deep Brain Stimulation (DBS) on autonomous responses
of PD subjects (Stemper et al., 2006; Ludwig et al., 2007). In
one of this analysis, including 14 patients, there was a mean
general decrease on blood pressure in on and off stimulation
status (Table 1), but the baroreflex responses were preserved
only when the stimulation was on, suggesting, therefore, a pos-
itive influence of the DBS in BP mediated by its influence on
central autonomous nervous system pathways (Stemper et al.,
2006). In another study comparing subthalamic DBS with a
pharmacotherapy-only group, no positive correlation was found
between the on-stimulation state and the decrease in blood pres-
sure; but this occurred in the only medicated group. Based on
this finding it was suggested that subthalamic DBS did not affect
cardiovascular autonomous responses (Ludwig et al., 2007). Note-
worthy, in a previous longitudinal study, the initial differences of
blood pressure were not found after 1 year’s follow-up, with a sim-
ilar mean blood-pressure decrease for the subthalamic DBS and
the only medicated groups (Holmberg et al., 2005). Additionally,
two other studies could not find differences in the cardiovascular
responses of the treated subjects (Lipp et al., 2005; Erola et al.,
2006).
In summary, subthalamic DBS could exert a neutral/positive
influence at the beginning of the therapy because of its direct
effects on central pathways, controlling autonomous responses
(Benedetti et al., 2004), or the accompanying decrease in med-
ication to subthalamic stimulation (Borgohain et al., 2012). This
effect seems to vanish with time (Holmberg et al., 2005). In addi-
tion, medial electrode placement in the subthalamus can produce
hypertensive crisis (authors experience; unpublished data). As
with the common prescribed drugs, further studies will help to
clarify the effect of DBS on this disabling symptom.
Apomorphine pump/apomorphine injections
Orthostatic hypotension has been reported since the early use of
apomorphine (Duby et al., 1972; Corsini et al., 1979). In these
initial descriptions, it was suggested that the peripheral DA dom-
peridone, could diminish this complication (Corsini et al., 1979)
recommending to pretreat patients 72 h before its administration.
A recent report with another peripheral blocker, commercialized
in the US, did not show this protective effect and only younger age
influenced the development of OH in apomorphine users (Ondo
et al., 2012).
The frequency of OH after apomorphine treatment is hetero-
geneous across the studies. The variability could be influenced, as
with the other treatments, by the definitions used (manometric vs.
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symptomatic), pressure cutoffs, and subsets of patients evaluated.
The figures oscillated between 1.9% (Tyne et al., 2004) and
more than 80% of the subjects affected (Duby et al., 1972). In
more recent reports, using current diagnostic criteria, a maxi-
mum of 17.6% of the subjects receiving 4 mg of apomorphine
had OH vs. 14.3% of the orally treated ones (no equivalent lev-
odopa doses reported). No clear differences between the two
groups were found (Pahwa et al., 2007b). The main decrease
in blood pressure was observed 20–40 min after the injection
(Table 1).
Continuous duodenal L-DOPA infusions
There are different evidences connecting continuous duodenal
l-DOPA infusions (CDLI) to OH (Pursiainen et al., 2012; Fer-
nandez et al., 2013). In a recent clinical trial interim analysis
(NCT00335153), 8.3% of the subjects had OH as an adverse event
related to this therapy (Fernandez et al., 2013). In a longitudinal
study involving nine CDLI cases an initial decrease of blood pres-
sure after the therapy instauration was observed (Table 1), but
after 2 months the figures rose again, suggesting a compensatory
mechanism (Pursiainen et al., 2012).
CONCLUSIONS ABOUT THE EFFECT OF PD THERAPIES ON OH
Many of the common prescribed treatments used for PD could
increase the frequency of OH. It seems advisable to monitor blood
pressure and this side effect when starting any “conventional med-
ication” or advanced PD therapy and when a dose adjustment is
required. If symptoms occur adjunctive therapies should be ini-
tiated (see non-pharmacological and pharmacological treatments
sections).
Other outcomes, like supine nocturnal hypertension (noctur-
nal BP means>120/70 mmHg) (Perez-Lloret et al., 2008), should
be addressed, as patients taking higher doses of dopaminergic
treatment had less decreases in SBP and DBP at night (Berganzo
et al., 2013).
Further studies are needed to clarify the adjusted effect of the
medication/treatments compared with the one produced by the
neurodegenerative process itself.
This will help to draw more specific conclusions for subsets of
subjects/treatments and anticipate the risk of OH, granting a more
individualized approach when treating PD patients.
THERAPEUTIC MEASURES
GENERAL CONSIDERATIONS
The common practice nowadays is to manage only the sympto-
matic cases, as no current therapy has yet evidenced a protective
action on the autonomic nervous system impairment and the role
of asymptomatic OH is still not defined (Low and Singer, 2008).
It should be stressed that there are not specifically designed
therapies for OH in PD subjects. This is linked to the methodolog-
ical concerns limiting most of the studies presented and making
the current evidence insufficient to define clear guidelines for the
management of OH in PD. Nevertheless, there are different ther-
apies that might be helpful (Lahrmann et al., 2006; Figueroa et al.,
2010; Zesiewicz et al., 2010; Seppi et al., 2011), which we will review
after this section.
An additional important feature to consider is that situations
of orthostatic stress (early hours of the morning, meals, physi-
cal activity among others) may trigger OH that otherwise may go
unnoticed (Low and Singer, 2008). Supine hypertension, an inter-
related aspect of OH defined as BP means>120/70 mmHg (Perez-
Lloret et al., 2008), should be also monitored (Low and Singer,
2008; Berganzo et al., 2013) as treatments used to increase blood
pressure, could lead to a worsening of this manifestation. Some
authors suggest that supine blood pressure should never exceed
180/110 mmHg (Low and Singer, 2008). In the case of hyper-
tensive patients, short half-life drugs are preferable and evening
administration.
Initially, it is also agreed to start with non-pharmacological
measures (Lahrmann et al., 2006), because of the lower likelihood
of adverse outcomes, the possibility of using them in moments of
orthostatic stress (Low and Singer, 2008) and for their simplicity
(Seppi et al., 2011).
NON-PHARMACOLOGICAL MEASURES
In Table 2 there is a description of the main employed strategies.
Water and salt
Standing-up implies that 500–700 ml of blood will pool in lower
extremities and abdomen (Diedrich and Biaggioni, 2004). This
is one of the reasons for trying to increase plasma volume to
counter this effect. Many studies have evaluated the influence of
drinking water on blood pressure (Jordan et al., 1999a; Senard
Table 2 | Non-pharmacological therapies.
Measure Increase on blood
pressure (mmHg)
% Compliance1 Comment
Fluid (water) intake 15–25 88 Recommended daily intake 2–2.5 l
Salt Intake 10–15 82 150–200 Na+ mmol/day (Salt: 9–12 g/day)
Meal frequency Unknown 82 Multiple smaller meals containing less carbohydrates
Alcohol consumption Unknown 59 Avoid its consume throughout the day
Night time head-up tilt 2–11 76 Elevated head of the bed (10–15 cm or 12°)
Stockings/abdominal bandages 12–26 59 Abdominal bandage more effective than stockings alone and
may favor compliance
Physical countermanouvers2 10–15 Unknown Leg crossing, squatting, bending-forward, and tiptoeing
1Based on Schoffer et al. (2007); 2 leg crossing, thigh contraction, or squatting.
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et al., 1999; Shannon et al., 2002; Mathias and Young, 2004;
Waters et al., 2005; Deguchi et al., 2007; Schoffer et al., 2007).
A positive effect has been found in autonomic disorders, includ-
ing multiple system atrophy or pure autonomic failure (Jordan
et al., 1999a; Shannon et al., 2002; Mathias and Young, 2004;
Waters et al., 2005; Deguchi et al., 2007). In PD subjects, no
difference in BP has been clearly evidenced, but the sample of
evaluated individuals was small (Senard et al., 1999; Schoffer
et al., 2007). In non-PD-related autonomic failure, blood-pressure
augmented once drinking 350–500 ml of water shortly after the
ingestion (20–35 min) with a mean increase ranging between 23
and 31 mmHg for SBP and 15–25 in DBP (Shannon et al., 2002;
Mathias and Young, 2004; Deguchi et al., 2007). This increase
is even comparable to the one obtained with some of the com-
monly prescribed medications for OH (Ten Harkel et al., 1994)
but lasted shortly (1 h) (Jordan et al., 1999a). It has been rec-
ommended to apply this strategy in the morning period, where
blood pressure is even lower (Omboni et al., 2001; Wieling
et al., 2002). The adverse outcomes are said to be mild (Schof-
fer et al., 2007), i.e., urinary incontinence. No follow-up data for
the long-term effect have been presented (Mathias and Young,
2004).
Salt ingestion could also increase plasma volume (Wieling
et al., 2002; Waters et al., 2005). One of the reasons to sup-
plement it, is that subjects with autonomic failure are unable
to reduce renal sodium excretion during salt restrictions, which
could potentially lead to an increase in the blood-pressure drop
upon standing (Wieling et al., 2002). The daily dietary average
intake of sodium is 150 mmol (Hollenberg, 2006). An increase
on blood pressure of 10–15 mmHg could be achieved with a
high-salt containing diet (150–200 mmol/day of sodium or 9–
12 g/day of common salt), combined with other measures (Wiel-
ing et al., 2002). It is necessary to check urine sodium (range
between 170 and 260 mmol/day) (Wieling et al., 2002), as well
as blood pressure (Hollenberg, 2006), to monitor the positive
effects and prevent any deleterious outcomes, as high-salt intake
could increase cardiovascular mortality (with urine sodium lev-
els above 300 mmol/day) (O’Donnell et al., 2011). One study
including PD cases failed to show this positive influence (Schof-
fer et al., 2007) after common salt supplements of 10–20 g/day
(170–350 mmol/day of sodium). Another aspect yet to be deter-
mined is the salt-sensitivity of PD subjects affected by OH, as
it is known that is not the same in all individuals (Hollenberg,
2006); further analyses are needed to clarify salt influence on OH
in PD.
Physical countermaneuvers
Several drills aimed to promote venous return and maintain car-
diac output have been proposed for different autonomic disorders
(Ten Harkel et al., 1992, 1994; Wieling et al., 1993; Bouvette et al.,
1996; Tutaj et al., 2006). They include tiptoeing, leg crossing,
bending-forward, and squatting (Ten Harkel et al., 1992, 1994;
Wieling et al., 1993; Bouvette et al., 1996; Tutaj et al., 2006). The
range of increase in blood-pressure fluctuated between 10 and
15 mmHg (Wieling et al., 1993). The importance of these maneu-
vers is still controversial (Ten Harkel et al., 1994; Bouvette et al.,
1996; Tutaj et al., 2006).
Stockings and abdominal bands
Besides the previous active maneuvers, there have been trials to
raise the peripheral vascular pressure passively based on studies
evaluating antigravity suits (Denq et al., 1997). This was aimed
to oppose the mentioned blood pooling upon standing, exerting
pressure on different capacitance beds such as the lower extremities
and abdomen (Denq et al., 1997). An abdominal band has shown
to be more effective and maybe with a better compliance, than the
usual recommended stockings (Schoffer et al., 2007). This band
could increase the blood pressure as much as 12 mmHg (Denq
et al., 1997; Tanaka et al., 1997). In a study including PD patients
30 mmHg pressure stockings failed to show any beneficial effect
on OH subjects (Schoffer et al., 2007).
Head-of-bed elevation
There is a physiological drop in blood pressure in the morning,
which has been related with night recumbence, although other
factors have not been ruled out (Omboni et al., 2001). In patients
with PD and autonomic failure, nocturnal hypertension leads to
natriuresis and polyuria, which, in turn, may cause severe OH
in the morning hours. Raising the head of the bed (10–15 cm or
12°) decreased the nocturnal blood-pressure levels and the release
of atrial natriuretic peptide, reducing nocturia, and OH in the
early hours of the morning, especially when combined with other
measures (Ten Harkel et al., 1992; van Lieshout et al., 2000). The
main increase in BP in non-PD cases ranged from 2 to 11 mmHg
and symptomatic relief has also been reported (Ten Harkel et al.,
1992).
Other proposed measures
Other proposed strategies are based on evidences of different
factors, which influence blood pressure in autonomic failure
(Lahrmann et al., 2006; Freeman, 2008; Gupta and Nair, 2008; Low
and Singer,2008; Mostile and Jankovic,2009). Frequent meals with
fewer carbohydrates could diminish the postprandial hypotension
component (Thomaides et al., 1993). It has been suggested that
food could lower blood pressure in autonomic failure through
vasodilatation (Thomaides et al., 1993; Chaudhuri et al., 1997)
and insulin secretion (Nozaki et al., 1993). Avoiding alcohol dur-
ing the day has been suggested (Chaudhuri et al., 1995; Narkiewicz
et al., 2000). Averting rapid postural changes and warm tempera-
tures and an adequate physical activity have been recommended
(Lahrmann et al., 2006; Freeman, 2008; Gupta and Nair, 2008;
Mostile and Jankovic, 2009). None of them have shown a favor-
able influence, when evaluated in PD individuals suffering from
OH (Schoffer et al., 2007).
PHARMACOLOGICAL MEASURES
When non-pharmacological therapies are not satisfactory, phar-
macological should be considered. Supine hypertension should be
always monitored, as some of the pharmacological therapies may
worsen it. Additionally, the long-term prognostic implications of
OH are not known, so the aim of the therapy focuses on ame-
liorating the symptoms. The main drugs used to treat OH, not
limited to PD, are summarized in Table 3. We describe the most
important ones.
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Table 3 | Pharmacological therapies.
Drug Dose Posology Increase on SBP/DBP
(mmHg)1
Adverse effects Comment
Pyridostigmine 30–60 mg b.i.d./t.i.d. Unknown/6.8 Abdominal colic, nausea, sialorrhea No supine hypertension
Fludrocortisone 0.1–0.2 mg/day q.d. 9–42/0–16 Hypokaliemia, edema, congestive
heart failure, supine hypertension
Effect may appear after 1–2 weeks
of treatment. Titer slowly
Midodrine 2.5–10 mg b.i.d./t.i.d. 20–22/11–15 Paresthesia, pruritus, piloerection,
supine hypertension
Tested in a randomized clinical trial
L-DOPS 200–400 mg q.d/b.i.d. 23–28/9–12 Dizziness, tiredness, visual
disturbance, supine hypertension,
malignant neuroleptic syndrome
High doses of DOPA-decarboxylase
inhibitors could abolish its effect
Octreotide 50–100µg q.d. No differences Injection-related, abdominal colic,
tiredness, headache
Useful for postprandial hypotension
Yohimbine 5 mg q.d 18–33/11–16 Nausea, tremor, confusion,
nervousness
May be useful in postprandial
orthostatic hypotension
Erythropoietin 25–75 UI/kg 3 times/week 16–19/16–17 Supine hypertension Only if concomitant anemia is
present
SBP, systolic blood pressure; DBP, diastolic blood pressure; 1values are rounded.
Fludrocortisone
Several studies have evaluated the effects of fludrocortisone on
OH based on its volume expanding (by means of enhancing renal
sodium reabsorption) and α-adrenoreceptor sensitizing activities
(Hoehn, 1975; Ten Harkel et al., 1992; Schoffer et al., 2007). The
common prescribed dosages range between 0.1 and 0.2 mg/day
(Low and Singer, 2008). Supine hypertension could worsen under
this treatment and other adverse outcomes like hypokalemia and
peripheral edema should be considered (Low and Singer, 2008).
The combining action with other non-pharmacological measures
like salt ingestion and head-up tilt has proved to be more effective
on increasing blood pressure (Ten Harkel et al., 1992).
Pyridostigmine
Pyridostigmine acts mainly improving ganglionic cholinergic
transmissions through cholinesterase inhibition. It favors normal
physiologic responses upon standing, without worsening supine
hypertension (Singer et al., 2006; Low and Singer, 2008). The
pressor effect was modest (a 6.4 mmHg increase in DBP) (Singer
et al., 2006), so it is recommended for initial treatment or mild
cases (Low and Singer, 2008). Doses are started at 30 mg b.i.d. or
t.i.d. and could be increased to 60 mg b.i.d. or t.i.d (Singer et al.,
2006). Adverse outcomes include diarrhea and nausea, among
other cholinergic symptoms (Singer et al., 2006; Low and Singer,
2008).
Midodrine
This drug is a α1-agonist with a short duration effect (2–4 h).
Its main action is to augment vascular resistance and therefore
blood pressure. In addition to the anti-OH effect, it can also
enhance supine hypertension, so close monitoring of recumbent
blood pressure and avoiding evening administration are required
(Jankovic et al., 1993; Low and Singer, 2008). Doses range between
2.5 and 10 mg b.i.d or t.i.d (Jankovic et al., 1993; Low et al., 1997).
Along with hypertension, other common adverse events are pilo-
erection, paresthesia, and itching (characteristically in the scalp)
(Jankovic et al., 1993; Low et al., 1997).
L-DOPS
l-Threo-dihydroxyphenylserine or droxidopa is a pro-drug con-
verted by DOPA decarboxylase into norepinephrine. Doses
between 100 and 900 mg have been used in PD and other auto-
nomic disorders, improving the drop in blood pressure in OH
significantly (Kaufmann, 2008; Mathias, 2008). Side effects were
mild, but supine hypertension should be monitored (Kaufmann,
2008). Noteworthy, DOPA-decarboxylase inhibitors used in high
doses (200 mg) could block this therapeutic effect (Kaufmann,
2008), but the current combinations employed with l-DOPA (25–
50 mg of inhibitor) do not produce this interference (Kaufmann,
2008). Recently, promising results suggesting a positive influence
on symptoms and OH related outcomes (falls and fall related
injuries) have been presented by Isaacson et al. (2013), American
Academy of Neurology, San Diego, CA, USA.
Other drugs
Many other medicaments have been attempted to correct the
effects of OH. The evidence in which they are based is weak,
mostly because of the small samples sizes and the designs used.
We describe some, but this is not intended to be an exhaustive
review of them.
Octreotide has been used mainly to correct postprandial
hypotension linked to OH (Hoeldtke and Israel, 1989), as it
could counter the release of vasoactive peptides secreted with
food/alcohol ingestion (Bordet et al., 1995; Chaudhuri et al., 1995;
Hoeldtke et al., 1998). Its combination with midodrine was more
effective than when it was given alone (Hoeldtke and Israel, 1989).
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The doses range from 50 to 100µg/kg (subcutaneous injection).
In some studies, no clear change of blood pressure could be
evidenced, but symptomatic relief was reported (Bordet et al.,
1995).
Yohimbine is an alpha-2 adrenergic receptor antagonist, which
enhances the residual sympathetic tone (Onrot et al., 1987; Shibao
et al., 2010). Some reports, including PD cases, have suggested a
positive role and even better results on raising blood pressure than
pyridostigmine (Shibao et al., 2010).
Erythropoietin has been useful in correcting a drop in blood
pressure in patients with concomitant anemia and autonomic
failure (Hoeldtke and Streeten, 1993; Perera et al., 1995).
Desmopressin studies have suggested a positive influence on
orthostatic tolerance (Mathias et al., 1986; Larina et al., 2009).
Desmopressin reduced nocturnal polyuria, raised supine blood
pressure, and reduced the postural fall, especially in the morning,
when patients were often at their worst (Mathias et al., 1986; Larina
et al., 2009).
Caffeine has been studied alone or in combination with ergot-
amine to treat OH and postprandial hypotension in subjects with
PD and other conditions causing autonomic failure (Lipsitz et al.,
1994; Dewey et al., 1998).
Domperidone (30 mg t.i.d), a dopaminergic antagonist, has
also shown beneficial effects on OH (Montastruc et al., 1985; Lang,
2001; Schoffer et al., 2007). It has also been recommended to treat
autonomic symptoms related to apomorphine (see above).
Ephedrine is an indirect sympathomimetic agent that has also
been used in OH (Brooks et al., 1989),but due to its central nervous
system actions, midodrine, that does not cross the blood-brain
barrier, may be preferred. Supine hypertension is also related to its
use (Brooks et al., 1989).
Etilefrine (5–10 mg) was used in 15 PD patients to increase
blood pressure upon standing (mean increase of 4.3%) reporting
only headaches as adverse outcomes (Miller et al., 1973).
Fluoxetine (20 mg) was used in a pilot study including 14 PD
patients, reducing the drop in blood pressure in 11 mmHg and
improving orthostatic symptoms (Montastruc et al., 1998).
For treating supine hypertension, it has been recommended to
use nitroglycerine patches (0.025–0.2 mg/h) (Jordan et al., 1999b),
or clonidine (0.1 mg) (Shibao et al., 2006), but further studies are
needed to measure the impact of this drugs on PD cases.
OVERALL SUMMARY
Orthostatic hypotension is a common and challenging symp-
tom affecting PD patients. The neurodegenerative process is
responsible for damaging the autonomous nervous system,
but anti-parkinsonian treatments could enhance the symptoms
derived from it. Current therapeutical strategies include non-
pharmacological and pharmacological measures aimed to favor
baropressor responses or to increase blood volume. There is insuf-
ficient evidence to recommend any specific treatment for the
PD-related autonomic failure. Therefore, it should be individual-
ized for the individual patient. Studies addressing the underscored
questions related to OH in PD are needed.
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